-46.8%
CPNG vs MRNA
+511.3%
-558.1%
-54.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.4% | -2.2% | +0.8% | -1.3% |
| 7D | -7.4% | +5.5% | -12.9% | -7.8% |
| 30D | -4.4% | +158.7% | -163.2% | -13.9% |
| 3M | -7.5% | +182.1% | -189.6% | -17.8% |
| 6M | -19.9% | +151.8% | -171.8% | -28.4% |
| YTD | -35.2% | +393.6% | -428.7% | -44.2% |
| 1Y | -46.8% | +499.5% | -546.2% | -54.4% |
| All | -46.8% | +511.3% | -558.1% | -54.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling